Ostarine MK-2866 Powder 1g

Description

Ostarine MK-2866 Powder — Research Overview

Ostarine (MK-2866, Enobosarm, GTx-024) is the most extensively clinically validated SARM, having completed multiple Phase II trials in cancer cachexia and muscle wasting. Developed by GTx Inc., it has the largest published clinical safety and efficacy dataset of any SARM, making it the reference compound for AR selectivity research.

Mechanism of Action

Ostarine is a partial AR agonist with high selectivity for muscle and bone tissue over androgenic organs. Its mechanism involves ligand-induced AR conformational change that recruits tissue-specific coactivator proteins — producing anabolic transcription in muscle without fully activating androgenic programs in prostate. This coactivator selectivity is the mechanistic basis of SARM tissue specificity.

Clinical Evidence Base

Phase II trials (Dalton et al., 2011; Crawford et al., 2016) demonstrated statistically significant improvements in total lean body mass and physical function in cancer patients at doses of 1–3mg/day over 12–16 weeks. Phase III ENOBOSARM trials showed lean mass preservation in non-small cell lung cancer patients during chemotherapy. This clinical dataset provides validated dosing references for preclinical-to-clinical translation research.

Powder Format for Research

Powder format supports receptor binding studies, cell culture anabolism assays, and pharmacokinetic research. Soluble in DMSO (≥50mg/mL), ethanol, and PEG400. For rodent studies, standard oral dosing is 1–10mg/kg/day in 1% methylcellulose suspension.

Purity: ≥98% (HPLC verified) | Format: Lyophilised powder | Quantity: 1g

For research use only. Not for human consumption.